Study guide
2.4 Survivorship
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
2.4 Survivorship
Key Takeaways Explain This Topic AI
Children's Oncology Group (COG) long-term follow-up is risk-adapted to treatment exposures; the nurse uses current institutional or COG-endorsed recommendations rather than memorizing a guideline version number as a pass/fail fact.
Every survivor needs a treatment summary plus a survivorship care plan that lists diagnosis, cumulative doses, radiation fields, surgeries, complications, surveillance tests, health promotion, and named clinicians.
Organ surveillance follows exposure: echocardiograms after anthracyclines, audiology after cisplatin, field-specific organ and second-cancer risk after radiation, and cognitive monitoring after CNS-directed therapy.
Fertility counseling belongs in survivorship even if banking was missed before therapy; alkylators, pelvic radiation, and HSCT are classic gonadotoxic exposures.
Adolescent and young adult (AYA) transition is a planned move of records, insurance, reproductive care, and late-effects follow-up into adult systems—not an abrupt discharge at the 18th birthday.
Last updated: August 2026
Survivorship is a phase of care, not a party at the end of treatment
A 16-year-old treated at age 4 for high-risk neuroblastoma received doxorubicin, cisplatin, and abdominal radiation. She feels "done," her local clinic closed the oncology chart, and no one has mentioned hearing, the heart, fertility, or who will see her at 21. Domain I.C tests whether the CPHON nurse can build long-term follow-up from exposures, not from a feeling that the cancer is over.
Cure is the goal; late effects are the durable cost. Survivorship begins at diagnosis in some models, but the exam's practical moment is the end of therapy: a written plan, a receiving clinician, and a family that can name risks without being terrified into skipping follow-up.
COG long-term follow-up principles
The Children's Oncology Group publishes long-term follow-up guidance used across North American pediatric centers. Principles that are testable:
Follow-up is risk-adapted . A child treated with surgery alone for low-stage Wilms tumor does not need the same cardiac schedule as a child who received high-dose anthracycline plus chest radiation.
Surveillance is organized by organ system and exposure (anthracycline dose, radiation field and dose, alkylators, platinum agents, HSCT, neurosurgery), not by a single "cancer survivor annual PET scan."
Recommendations evolve. Use the current COG-endorsed or institutional pathway. Do not treat a specific COG version number as a pass/fail fact.
Health promotion (activity, dental care, sun protection, immunizations, tobacco, HPV) sits inside survivorship, not in a separate wellness silo.
The nurse's job is to know which exposures drive which tests , and to get the child into a late-effects clinic that applies the current tables.
Treatment summary and survivorship care plan
These are two related documents; both should travel with the family.
Treatment summary (what was done):
Diagnosis, site, stage/risk group, date of diagnosis and of end of therapy.
Protocol name and treating center.
Chemotherapy agents with cumulative doses that drive late effects (doxorubicin or daunorubicin in mg/m², cyclophosphamide or ifosfamide, cisplatin or carboplatin).
Radiation: fields, laterality, dose, boosts (brain, spine, chest, abdomen, neck, total body).
Surgeries, including nephrectomy, amputation or limb salvage, central-line history, neurosurgery.
HSCT: autologous versus allogeneic, graft-versus-host disease, conditioning.
Major complications: intensive-care stays, thrombosis, sinusoidal obstruction, significant infections.
Survivorship care plan (what happens next):
Who is the late-effects clinician versus the PCP.
Surveillance calendar: echocardiogram, electrocardiogram, audiology, pulmonary function, thyroid labs, colorectal or breast screening when radiation fields require them, neuropsychological testing.
Vaccination catch-up status.
Fertility, psychosocial, school/work, and second-cancer counseling.
Emergency problems that still go to oncology (for example, a survivor still with a port, or very recent therapy).
A family should leave the end-of-therapy visit able to hand a new adult internist a document that lists doxorubicin 300 mg/m² and cisplatin with documented hearing loss , not a smile and "she had neuroblastoma."
Organ-specific surveillance the exam expects you to pair
Exposure Late-effect risk Surveillance example
Anthracyclines (doxorubicin, daunorubicin, idarubicin, mitoxantrone) Cardiomyopathy, arrhythmia Echocardiogram ± electrocardiogram on a risk-adapted interval
Cisplatin or carboplatin Sensorineural hearing loss, renal tubular injury Audiology; renal labs and blood pressure
Radiation, field-specific Second cancers and organ injury in the beam Neck: thyroid. Chest: heart, lungs, breast tissue in females. Abdomen: bowel, kidney, uterus/ovaries. Brain/spine: cognition, hormones, hearing, stroke risk
CNS therapy (cranial radiation, intrathecal methotrexate, high-dose methotrexate) Processing speed, working memory, attention, endocrine deficits School screening, neuropsychological testing, endocrine referral
Alkylators, pelvic radiation, HSCT Gonadal failure, infertility, premature menopause Fertility counseling, endocrine labs, reproductive referral
Do not invent a universal echo interval as the only correct number; intensity and frequency rise with cumulative anthracycline dose and chest radiation. The testable claim is that echocardiography belongs in the plan after anthracyclines , not that every survivor is screened identically.
A 11-year-old three years off medulloblastoma therapy (craniospinal radiation plus cisplatin) who is failing math needs cognitive late-effects screening and neuropsychological testing , plus ongoing audiology—not reassurance that school trouble is unrelated.
Fertility counseling
Counseling starts before gonadotoxic therapy when feasible (sperm banking; oocyte or ovarian-tissue pathways where available and time allows) and continues in survivorship . Adolescents who were toddlers at diagnosis still deserve a private conversation at a developmentally right age: what was given, what is known, what is unknown, contraception if gonadal function recovered, and referral to reproductive endocrinology rather than "wait until you want children." Gender-sensitive, parent-inclusive but teen-private practice matters in AYA clinics.
Psychosocial re-entry
Survivors may have medical trauma, "scanxiety," social lag after years of isolation, sibling resentment, and financial stress. Re-entry to school and sport is a nursing coordination task: 504/IEP updates, fatigue, hearing-assist devices after cisplatin, and coach education after cardiotoxic therapy (no unrestricted elite training until cardiology clears). Depression, suicidal thinking, and substance use are screened; they are not "ungrateful survivor" behavior.
Transition from pediatric to adult survivorship (AYA)
Pediatric clinics do not own the survivor forever. Around late adolescence—timing is individual , not a magic 18th-birthday dump—the nurse plans:
A portable treatment summary and care plan the young person can explain.
Adult late-effects or primary care that accepts the document, not a random walk-in clinic with no echo order.
Insurance, reproductive health, mental health, and how to access records.
Self-management: the 16-year-old who still sits silently while a parent lists medications is not ready; teach in layers.
A 19-year-old ALL survivor walking into adult primary care without a cumulative anthracycline dose is a failed transition, even if the leukemia remains in remission.
Survivorship nursing is exposure-based surveillance plus a document and a receiving adult system. The CPHON nurse who only celebrates the bell has left half the work undone.